ImmuPharma (GB:IMM) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuPharma PLC, a specialist in drug discovery and development, has successfully passed all resolutions at its recent AGM, indicating robust shareholder confidence. The company, known for its innovative peptide therapeutics, including a promising lupus treatment, continues to maintain its strong corporate governance and strategic direction.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.